Tarceva increased disease control rate (CR+PR+SD) by 60% [1,2]

• In the overall study population, 60% more patients in the Tarceva arm achieved disease control (CR+PR+SD) than in the placebo arm (44.0% vs 27.5%). [1,2]
• The median duration of disease control was 6.0 months (95% CI=5.7–7.4; n=188) in the Tarceva arm and 4.7 months (95% CI=3.7–5.5; n=58) in the placebo arm (HR=0.53; P=0.0002). [2]
• In patients with a response to Tarceva, the median duration of response (CR+PR) was 7.9 months (n=38). [1,2]